Theranos, a $9 billion health care startup, is becoming a poster child for the limited value of having a board stocked with Washington powerbrokers. With insiders ranging from Henry Kissinger to former Senate Majority Leader Bill Frist, Theranos still faces a federal regulatory call Friday that could capsize the firm and threaten an innovative healthcare sector along with it.
The Palo Alto, Calif., company, headed by 32-year-old Elizabeth Holmes, has faced growing scientific and financial skepticism over its bold central claim: that it can replace the scary hypodermic needle with a cheap finger prick to test human blood, overturning the lab testing industry in the process. For the full article click here
from health IT caucus http://ift.tt/1QbKhee
via IFTTT
No comments:
Post a Comment